Real questions from health communities, answered with cited research from PubMed and Vellito's article corpus. Plain language, no medical advice. How this works.
A 2024 trial found that a sirolimus-eluting iron bioresorbable scaffold did not perform as well as standard metallic stents for treating coronary artery disease in patients with…
Yes, the sirolimus-eluting iron scaffold (IBS) showed higher late lumen loss than the everolimus-eluting stent at 2 years in the IRONMAN-II trial.
Researchers use mice and rats with diet-induced obesity, heart attacks, or specific genetic changes to study cardiometabolic diseases like heart failure and diabetes.
Researchers induce cardiometabolic disease in mice primarily by feeding them a high-fat diet, often combined with chemical treatments like VCD to mimic postmenopausal states.
Yes, the ALBI score can predict mortality risk after NSTEMI, with higher scores indicating a significantly higher risk of death.
Research suggests ginsenoside CK has antiarrhythmic potential and can protect the heart from injury in models of ischemia, sepsis, and chemotherapy, though clinical use is still…
Yes, colchicine can help reduce plaque in coronary atherosclerosis by lowering inflammation, though evidence on direct plaque volume reduction is mixed.
Treating coronary atherosclerosis now requires a dual-axis framework that lowers lipids and targets inflammation, moving beyond just fixing blocked arteries to stabilizing the…
Combined therapies work by lowering LDL cholesterol while simultaneously reducing the chronic inflammation that drives plaque growth and rupture.
Yes, echocardiographic strain imaging, especially the apical sparing ratio, can help detect cardiac amyloidosis in patients with left ventricular hypertrophy, but its accuracy is…
For women with ANOCA/INOCA, intensive medical treatment did not reduce major adverse cardiovascular events over 2.5 years compared to usual care.
Having ANCA-associated vasculitis significantly increases your risk of heart attacks, strokes, blood clots, and death compared to people without the disease.
Yes, a prior history of atrial fibrillation is linked to a higher risk of sudden cardiac death, especially in patients with heart attack or heart failure.
Yes, finerenone reduces cardiovascular death and worsening heart failure events in patients with heart failure with mildly reduced ejection fraction, based on a network…
Yes, SGLT2 inhibitors are effective for treating heart failure with mildly reduced ejection fraction, reducing heart failure hospitalizations and improving outcomes.
Yes, a history of pre-eclampsia is linked to a higher risk of later heart disease, likely due to early blood vessel damage that can be detected years after pregnancy.
Complex PCI carries a higher risk of major bleeding compared to non-complex PCI, with studies showing a 24% increased hazard for bleeding events.
ESAs reduce total heart failure hospitalizations and improve hemoglobin and exercise tolerance, but do not lower first hospitalization or mortality risk.
Going to a hospital with higher cardiac capability significantly lowers the risk of death for patients with cardiogenic shock compared to lower-tier facilities.
An IABP may improve survival chances in advanced cardiogenic shock, but results are mixed and depend on the patient's specific condition.
Yes, observational studies suggest pulmonary artery catheter use is linked to lower in-hospital mortality in cardiogenic shock, but randomized trials are lacking.
Immediate surgery does not improve outcomes for all STEMI patients with multivessel disease, and it may increase risks for those with heart failure.
For STEMI with multivessel disease, immediate and staged revascularization show similar outcomes overall, but staged may be safer in patients with heart failure or cardiogenic…
For most patients with STEMI and multivessel disease, immediate and staged revascularization have similar risks of death or heart attack, but staged may reduce the need for…
We pull real patient questions from public Reddit health communities (r/AskDocs, r/diabetes, r/menopause, etc.). Each question is rewritten into a generic medical question (no personal details), then answered by an AI using only cited sources from Vellito's article database and PubMed. A second AI independently scores each answer for accuracy and citation fidelity before publication. Answers below the safety threshold or touching emergency, dosing, or pediatric topics are queued for human review and never auto-published.
This is not medical advice. Always speak with your own doctor before making decisions about your health.